Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study

被引：0
|
作者：
Peng, Peijian
Xu, Xiaolu
Zhong, Jincai
Ye, Jin-Hui
Wang, Zhi-Hui
Wang, Hong
Lin, Hong
Du, Caiwen
Zou, Guorong
Ouyang, Jie
Shi, Ying-ying
Xu, Fei
Yu, Gengsheng
Lu, Yongkui
Wang, Yong-Xia
Cui, Shi-En
Li, Lu-Zhen
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Dept Breast Dis, Zhuhai, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] First Peoples Hosp Zhaoqing, Dept Breast Oncol, Zhaoqing, Peoples R China
[4] Jiangmen Cent Hosp, Jiangmen, Peoples R China
[5] Zhuhai Matern & Child Hlth Hosp, Dept Breast Surg, Zhuhai, Guangdong, Peoples R China
[6] Zhuhai Hosp Integrated Tradit Chinese & Western M, Dept Breast Dis, Zhuhai, Guangdong, Peoples R China
[7] Chinese Acad Med Sci, Canc Hosp, Shenzhen Ctr, Shenzhen, Peoples R China
[8] Panyu Cent Hosp, Guangzhou, Peoples R China
[9] Dongguan Peoples Hosp 3, Dongguan, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[11] State Key Lab Oncol South China, Guangzhou, Peoples R China
[12] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[13] Guangxi Med Univ Canc Ctr, Guangxi, Peoples R China
[14] Dongguan Peoples Hosp, Dongguan, Peoples R China
[15] Zhongshan City Peoples Hosp, Dept Gen Surg, Breast Ctr, Zhongshan, Peoples R China
[16] Guangzhou Univ Tradit Chinese Med, Zhongshan Hosp Tradit Chinese Med, Zhongshan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13139
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study
    Peng, PeiJian
    Xu, Xiao-Lu
    Zhong, Jin-Cai
    Ye, Jin-Hui
    Wang, Zhi-Hui
    Wang, Hong
    Lin, Hong
    Du, Cai-Wen
    Zou, Guorong
    Ouyang, Jie
    Shi, Ying-Ying
    Xu, Fei
    Yu, Geng-Sheng
    Lu, Yong-Kui
    Wang, Yong-Xia
    Cui, Shi-En
    Li, Lu-Zhen
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study
    Peng, Peijian
    Xu, Xiaolu
    Zhong, Jincai
    Lin, Hong
    Wang, Hong
    Ye, Jin-Hui
    Du, Caiwen
    Wang, Zhi-Hui
    Yu, Gengsheng
    Zou, Guorong
    Ouyang, Jie
    Wang, Yong-Xia
    Li, Lu-Zhen
    Xu, Fei
    Cui, Shi-En
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study
    Yin, Y.
    Wu, X.
    Huang, X.
    Li, W.
    Hua, Y.
    Liang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S648 - S649
  • [4] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study.
    Yin, Yongmei
    Wu, Xinyu
    Hua, Yijia
    Sun, Chunxiao
    Liang, Yan
    Yang, Fan
    Huang, Xiang
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Safety and efficacy of eribulin as second-line treatment for HER2-negative metastatic breast cancer.
    Michalaki, Vasiliki
    Psychogios, John
    Contis, John
    Kondi, Agathi
    Gennatas, Constantine
    Papadimitriou, Christos A.
    Vasiliou, John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kimura, Kosei
    Iwamoto, Mitsuhiko
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
  • [7] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kosei Kimura
    Mitsuhiko Iwamoto
    Satoru Tanaka
    Daigo Yamamoto
    Katsuhide Yoshidome
    Hiroyuki Ogura
    Risa Terasawa
    Nobuki Matsunami
    Yuko Takahashi
    Toshikatsu Nitta
    Takashi Morimoto
    Hiroya Fujioka
    Kanako Kawaguchi
    Kazuhisa Uchiyama
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
  • [8] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
    Takashima, Tsutomu
    Tokunaga, Shinya
    Tei, Seika
    Nishimura, Shigehiko
    Kawajiri, Hidemi
    Kashiwagi, Shinichiro
    Yamagata, Shigehito
    Noda, Satoru
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    SPRINGERPLUS, 2016, 5 : 1 - 8
  • [9] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
  • [10] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
    Perez-Garcia, Jose M.
    Llombart-Cussac, Antonio
    Cortes, Maria G.
    Curigliano, Giuseppe
    Lopez-Miranda, Elena
    Alonso, Jose L.
    Bermejo, Begona
    Calvo, Lourdes
    Caranana, Vicente
    de la Cruz Sanchez, Susana
    Vazquez, Raul M.
    Prat, Aleix
    Borrego, Manuel R.
    Sampayo-Cordero, Miguel
    Segui-Palmer, Miguel A.
    Soberino, Jesus
    Malfettone, Andrea
    Schmid, Peter
    Cortes, Javier
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394
12345